Rapport Therapeutics (RAPP) CEO Ceesay Sells 8,210 Shares

What Happened

• Ceesay Abraham, Chief Executive Officer of Rapport Therapeutics, sold a total of 8,210 shares in open-market transactions on July 14, 2026. The sales were reported as: 5,481 shares at a weighted-average price of $39.72 (proceeds $217,715) and 2,729 shares at a weighted-average price of $40.57 (proceeds $110,722), for aggregate proceeds of approximately $328,437. These were sales (not purchases), commonly viewed as routine insider selling.

Key Details

• Transaction date: July 14, 2026; Form 4 filed July 15, 2026 (timely filing).
• Reported prices and proceeds: 5,481 @ $39.72 = $217,715; 2,729 @ $40.57 = $110,722; total ≈ $328,437.
• Footnotes: Sales were effected under Rule 10b5-1 trading plans adopted March 27, 2026 (F1). Reported prices are weighted averages; individual trade prices ranged $39.36–$40.35 for the first lot and $40.37–$40.73 for the second (F2, F3). The reporting person will provide detailed per-price breakdowns on request.
• Ownership note: Certain shares are held by The Ceesay Family Irrevocable Trust and The Dorothy Ceesay Irrevocable Trust (u/d/t March 27, 2024); the reporting person disclaims beneficial ownership of those trust shares except to the extent of any pecuniary interest (F4, F5).
• Filing timeliness: Not marked late; filed within required Form 4 window.

Context

• These were outright sales under a pre-established 10b5-1 plan; such programmatic sales are common for insiders to diversify or meet liquidity needs and do not necessarily reflect a change in view about the company.
• No purchase, option exercise, gift, or tax-withholding event was reported in this filing. The filing does not disclose post-transaction total holdings for the reporting person.